KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Current Assets (2016 - 2025)

Historic Current Assets for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $13.9 billion.

  • Teva Pharmaceutical Industries' Current Assets rose 1110.58% to $13.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $13.9 billion, marking a year-over-year increase of 1110.58%. This contributed to the annual value of $13.9 billion for FY2025, which is 1110.58% up from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Current Assets stood at $13.9 billion for Q4 2025, which was up 1110.58% from $12.7 billion recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Current Assets ranged from a high of $13.9 billion in Q4 2025 and a low of $11.4 billion during Q3 2023
  • In the last 5 years, Teva Pharmaceutical Industries' Current Assets had a median value of $12.3 billion in 2024 and averaged $12.3 billion.
  • In the last 5 years, Teva Pharmaceutical Industries' Current Assets plummeted by 762.99% in 2023 and then skyrocketed by 1110.58% in 2025.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Current Assets stood at $12.6 billion in 2021, then decreased by 4.15% to $12.1 billion in 2022, then rose by 3.6% to $12.5 billion in 2023, then rose by 0.54% to $12.6 billion in 2024, then rose by 11.11% to $13.9 billion in 2025.
  • Its last three reported values are $13.9 billion in Q4 2025, $12.7 billion for Q3 2025, and $12.6 billion during Q2 2025.